The U.S. central lab market size was estimated at USD 2.37 billion in 2025 and is predicted to increase from USD 2.58 billion in 2026 to approximately USD 5.19 billion by 2035, expanding at a CAGR of 8.08% from 2026 to 2035. The market is growing need for accurate sampling analysis, efficient clinical trial management, and regulatory-compliant laboratory services in drug development. Increasing focus on personalized therapies, complex multi-site studies, and advanced diagnostics technologies is further strengthening the role of central laboratories in the healthcare and research ecosystem.
A U.S. central lab is a specialized facility that provides standardized testing and analysis of clinical trial samples to ensure consistent, reliable, and regulatory-compliant research across multiple study sites. The U.S. central lab market is growing due to increasing complexity in clinical trials and the need for consistent, high-quality laboratory data across multiple sites. Rising focus on personalized medicine, growing af advanced diagnostic tools, and higher outsourcing of trial testing to specialized labs are further supporting demand. Additionally, stricter regulatory timelines are strengthening market growth.
The U.S. central lab market is expected to grow with rising demand for precision medicine, increasing multi-site clinical trials, and a stronger focus on rare disease and oncology research. Expansion of advanced biomarker testing and improved digital connectivity for faster sample tracking and reporting will further enhance efficiency and create new growth opportunities for central laboratories.
| Parameter | Value |
| Active clinical trials (U.S.) | 10,000+ |
| CLIA-certified laboratories | 260,000+ |
| FDA-regulated clinical studies | 5000+ |
| Average phase III trial | duration1-4 years (FDA guidance) |
The U.S. central lab ecosystem is supported by a vast network of certified laboratories and a high volume of ongoing clinical trials regulated by NIH and FDA. This strong infrastructure ensures standardized testing, regulatory compliance, and reliable data generation, making central laboratories essential for efficient and high-quality clinical research and drug development processes.
The biomarker testing services segment held a dominant share of 31% in 2025 and is expected to grow at the fastest CAGR of 9.8% in the market during the forecast period due to its critical role in precision medicine and targeted drug development. It helps identify disease mechanisms, predict treatment response, and improve patient selection in clinical trials. Growing oncology research, increasing demand for personalized therapies, and widespread adoption of molecular and genetic profiling in drug pipelines are further strengthening its leading position.
The oncology segment led the U.S. central lab market with a share of 38% in 2025 and is expected to grow at the fastest CAGR of 10.2% in the market during the forecast period due to the high burden of cancer and the number of oncology-focused clinical trials. Cancer research relies heavily on biomarker analysis, genetic profiling, and companion diagnostics to support precision medicine approaches. Continuous innovation in targeted therapies, strong pharmaceutical investment, and the need for accurate, standardized testing in complex studies further drive the dominance of this therapeutic area.
The phase III segment dominated the U.S. central lab market with a share of 45% in 2025 and is expected to grow at the fastest CAGR of 8.7% in the market during the forecast period due to the large scale, complexity, and regulatory importance of late-stage clinical trials. These studies involve an extensive patient population across multiple sites, requiring standardized testing, high-quality data management, and strict compliance. Central laboratories play a crucial role in ensuring the accuracy, consistency, and reliability of results needed for regulatory approval of new drugs and therapies.
The pharmaceutical companies segment dominated the U.S. central lab market with a share of 42% in 2025 due to their extensive involvement in drug discovery, development, and large-scale clinical trials. These companies rely heavily on centralized laboratory services for standardized testing, biomarker analysis, and regulatory-compliant data generation. Strong R&D investments, robust drug pipelines, and increasing global trial activities further strengthen their leading position as the primary end users of central lab services.
The genetic testing segment led the U.S. central lab market with a share of 29% in 2025 and is estimated to grow at the fastest CAGR of 10.40% during the forecast period due to falling sequencing costs, rising cancer rates, and demand for personalized medicine. It enables precise, early disease diagnosis and targeted therapies. In clinical trials, it helps monitor drug efficacy and patient outcomes. These benefits make genetic tools essential in routine diagnostics and pharmaceutical research.
The molecular diagnostics segment held a dominant share of 26% in the U.S. central lab market in 2025 due to its high accuracy in detecting genetic and molecular-level disease changes. It is widely used in oncology, infectious diseases, and personalized medicine trials. Growing adoption of PCR, sequencing technologies, and biomarker-based testing, along with increasing demand for early diagnosis and targeted therapies, continues to strengthen its leadership position.
Leading companies in the market include Labcorp, Quest Diagnostics, IQVIA, Thermo Fisher Scientific, and Medpace. These players are strengthening market growth through advanced clinical trial laboratory services, biomarker and genetic testing, and integrated data management solutions. Continuous investments in automation, precision medicine capabilities, and large-scale clinical research partnerships are further enhancing their leadership in the U.S. central lab landscape.
By Service Type
By Therapeutic Area
By Phase
By End User
By Test Type
By Technology
